LKQ Corporation's shares remain attractive despite recent declines in revenue and profit, mainly due to temporary ERP implementation challenges in Europe rather than reduced demand. Management projects a slight revenue drop of 1–3% by 2026 and adjusted earnings per share between $2.60 and $2.90, with ongoing restructuring aimed at boosting long-term profitability. The stock is considered undervalued compared to peers, offering significant upside potential if valuation multiples normalize. Investors may find further price drops a buying opportunity.
LKQ Corporation's recent share performance is noted here for context. For readers following Consumer Cyclical stocks, here is Pluang's market snapshot as of Oct 19, 2026 17:11 WIB: out of 134 priced US stocks in the sector, 75 rose and 29 fell today. Notable movers include Packaging Corporation of America (PKG) at USD 231.97 with a 1-day change of -1.71% and a typical hold time on Pluang of 48 days, Victoria's Secret & Co (VSXY) at USD 88.80 with a 1-day change of +1.67% and a typical hold time of 34 days, and Aterian Inc (ATER) at USD 0.57 with a 1-day change of +1.60% and a typical hold time of 27 days.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
